Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 07/28 02:15:57 pm
381.9 DKK   +1.09%
08:31a DIAMYD MEDICAL : Companion Medical receives FDA clearance
07/25 NOVO NORDISK A/ : - Share repurchase programme
07/23 NOVO NORDISK A/ : 66% of diabetes sufferers unaware
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/13/2012 | 10:15am CEST
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
08:31a DIAMYD MEDICAL : Companion Medical receives FDA clearance
07/25 NOVO NORDISK A/S : - Share repurchase programme
07/23 NOVO NORDISK A/S : 66% of diabetes sufferers unaware
07/21 NOVO NORDISK A/S : Researchers at Novo Nordisk Report New Data on Stem Cell Rese..
07/21 NOVO NORDISK A/S : The Digital Health Connection in Africa
07/18 NOVO NORDISK A/S : - Share repurchase programme
07/14 NOVO NORDISK A/S : Unique New Book Series from Novo Nordisk and JDRF Uses Custom..
07/12 NOVO NORDISK A/S : to present 28 abstracts at the World Federation of Hemophilia..
07/11 NOVO NORDISK A/S : - Share repurchase programme
07/07 NOVO NORDISK A/S : Inc. Partners with Tony Award®-Winning Actor and Entertainer ..
More news
Sector news : Pharmaceuticals - NEC
01:42pDJALEXION PHARMACEUTICALS : Cuts Profit Guidance
01:35pDJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
01:16pDJBRISTOL MYERS SQUIBB : -Myers Results Boosted by Cancer Drugs
12:49p AstraZeneca a takeover target again? CEO not commenting
10:16aDJASTRAZENECA : Posts $3 Million Loss
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/21 The End Of Another Chapter In Obesity Drug Development
07/20 Vivus Begins Q3 With Underwhelming Qsymia Sales
07/19 Arena - Belviq Scripts Start Q3 In Tough Shape
07/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2016 Update
Advertisement
Financials ( DKK)
Sales 2016 114 734 M
EBIT 2016 49 682 M
Net income 2016 38 844 M
Finance 2016 10 619 M
Yield 2016 1,91%
P/E ratio 2016 24,52
P/E ratio 2017 22,02
EV / Sales 2016 6,53x
EV / Sales 2017 6,04x
Capitalization 760 347 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 402  DKK
Spread / Average Target 6,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-4.68%113 127
JOHNSON & JOHNSON21.47%343 198
PFIZER INC.14.16%223 490
ROCHE HOLDING LTD.-9.99%216 972
NOVARTIS AG-5.30%216 918
MERCK & CO., INC.10.94%162 206
More Results